Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Curalogic's CEO and CFO resign

This article was originally published in Scrip

Executive Summary

Two top executives at the Danish pharmaceutical company Curalogic have resigned, as the company looks likely to go into liquidation. CEO Peter Moldt and CFO Helle Busck Fenavig will stay on until the company re-establishes a biotechnology pipeline or pays cash and cash equivalents back to shareholders, which is still expected to take place this year. Curalogic decided to stop developing its pipeline of oral immunotherapies this year. Last December top-line Phase III data showed that the dose of its ragweed allergy treatment was ineffective. The ragweed pollen extract reached the immune system, but the company could not determine why the dose was ineffective and finding the optimal formulation would require more research. Curalogic said that the development of its pipeline would be set back by several years and increase the risk profile. Subsequently, it planned to license in new, less risky products to replace its pipeline. An analyst told Scrip that the company was unlikely to find new products as it has failed to do so since the beginning of the year. He said that the company had not made a public announcement about going into liquidation, but this was the most likely scenario. The company was unavailable for comment.

You may also be interested in...



Innovation not M&A to drive Bayer growth in LatAm

Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.

2010 Scrip 100 - Is Anvisa a friend of innovators?

A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.

Elan raises $1.5 billion

Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.

Topics

Related Companies

UsernamePublicRestriction

Register

SC024724

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel